Literature DB >> 20631143

Infection by discordant strains of HIV-1 markedly enhances the neutralizing antibody response against heterologous virus.

Rebecca L R Powell1, Thompson Kinge, Phillipe N Nyambi.   

Abstract

High-risk cohorts in East Africa and the United States show rates of dual HIV-1 infection--the concomitant or sequential infection by two HIV-1 strains--of 50% to 100% of those of primary infection, and our normal-risk HIV-positive cohort in Cameroon exhibits a rate of dual infection of 11% per year, signifying that these infections are not exceptional. Little is known regarding the effect of dual infections on host immunity, despite the fact that they provide unique opportunities to investigate how the immune response is affected when challenged with diverse HIV-1 antigens. Using heterologous primary isolates, we have shown here that dual HIV-1 infection by genetically distant strains correlates with significantly increased potency and breadth of the anti-HIV-1 neutralizing antibody response. When the neutralization capacities of sequential plasma obtained before and after the dual infection of 4 subjects were compared to those of matched plasma obtained from 23 singly infected control subjects, a significant increase in the neutralization capacity of the sequential sample was found for 16/28 dually infected plasma/virus pairs, while only 4/159 such combinations for the control subjects exhibited a significant increase (P < 0.0001). Similarly, there was a significant increase in the plasma dilution capable of neutralizing 50% of virus (IC(50)) for 18/24 dually infected plasma/virus pairs, while 0/36 controls exhibited such an increase (P < 0.0001). These results demonstrate that dual HIV-1 infection broadens and strengthens the anti-HIV-1 immune response, suggesting that vaccination schemes that include polyvalent, genetically divergent immunogens may generate highly protective immunity against any HIV-1 challenge strain.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20631143      PMCID: PMC2937625          DOI: 10.1128/JVI.02732-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  Incidence of HIV superinfection following primary infection.

Authors:  Davey M Smith; Joseph K Wong; George K Hightower; Caroline C Ignacio; Kersten K Koelsch; Eric S Daar; Douglas D Richman; Susan J Little
Journal:  JAMA       Date:  2004-09-08       Impact factor: 56.272

2.  A resting cell assay for improved detection of antibody-mediated neutralization of HIV type 1 primary isolates.

Authors:  S Zolla-Pazner; S Sharpe
Journal:  AIDS Res Hum Retroviruses       Date:  1995-12       Impact factor: 2.205

3.  Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT.

Authors:  Priscilla Swanson; Carmen de Mendoza; Yagnya Joshi; Alan Golden; Richard L Hodinka; Vincent Soriano; Sushil G Devare; John Hackett
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

4.  In-depth analysis of a heterosexually acquired human immunodeficiency virus type 1 superinfection: evolution, temporal fluctuation, and intercompartment dynamics from the seronegative window period through 30 months postinfection.

Authors:  F E McCutchan; M Hoelscher; S Tovanabutra; S Piyasirisilp; E Sanders-Buell; G Ramos; L Jagodzinski; V Polonis; L Maboko; D Mmbando; O Hoffmann; G Riedner; F von Sonnenburg; M Robb; D L Birx
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

5.  In-depth, longitudinal analysis of viral quasispecies from an individual triply infected with late-stage human immunodeficiency virus type 1, using a multiple PCR primer approach.

Authors:  M Gerhardt; D Mloka; S Tovanabutra; E Sanders-Buell; O Hoffmann; L Maboko; D Mmbando; D L Birx; F E McCutchan; M Hoelscher
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

6.  Evidence for frequent reinfection with human immunodeficiency virus type 1 of a different subtype.

Authors:  Bhavna Chohan; Ludo Lavreys; Stephanie M J Rainwater; Julie Overbaugh
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

Review 7.  Application of the polyvalent approach to HIV-1 vaccine development.

Authors:  Julia L Hurwitz; Karen S Slobod; Tim D Lockey; Shixia Wang; Te-Hui W Chou; Shan Lu
Journal:  Curr Drug Targets Infect Disord       Date:  2005-06

8.  Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.

Authors:  Shixia Wang; Ranajit Pal; John R Mascola; Te-Hui W Chou; Innocent Mboudjeka; Siyuan Shen; Qin Liu; Stephen Whitney; Timothy Keen; B C Nair; V S Kalyanaraman; Philip Markham; Shan Lu
Journal:  Virology       Date:  2006-04-17       Impact factor: 3.616

9.  Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range.

Authors:  N R Landau; K A Page; D R Littman
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

10.  Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage.

Authors:  D Cecilia; V N KewalRamani; J O'Leary; B Volsky; P Nyambi; S Burda; S Xu; D R Littman; S Zolla-Pazner
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

View more
  23 in total

1.  Potent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 (HIV-2) from HIV-1.

Authors:  Gülsen Ozkaya Sahin; Birgitta Holmgren; Zacarias da Silva; Jens Nielsen; Salma Nowroozalizadeh; Joakim Esbjörnsson; Fredrik Månsson; Sören Andersson; Hans Norrgren; Peter Aaby; Marianne Jansson; Eva Maria Fenyö
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  Intrasubtype B HIV-1 Superinfection Correlates with Delayed Neutralizing Antibody Response.

Authors:  Gabriel A Wagner; Elise Landais; Gemma Caballero; Pham Phung; Sergei L Kosakovsky Pond; Pascal Poignard; Douglas D Richman; Susan J Little; Davey M Smith
Journal:  J Virol       Date:  2017-08-10       Impact factor: 5.103

Review 3.  How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?

Authors:  Per Johan Klasse; Rogier W Sanders; Andrea Cerutti; John P Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2011-05-20       Impact factor: 2.205

4.  Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop.

Authors:  Penny L Moore; Elin S Gray; Daniel Sheward; Maphuti Madiga; Nthabeleng Ranchobe; Zhong Lai; William J Honnen; Molati Nonyane; Nancy Tumba; Tandile Hermanus; Sengeziwe Sibeko; Koleka Mlisana; Salim S Abdool Karim; Carolyn Williamson; Abraham Pinter; Lynn Morris
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

5.  Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies.

Authors:  Penny L Moore; Daniel Sheward; Molati Nonyane; Nthabeleng Ranchobe; Tandile Hermanus; Elin S Gray; Salim S Abdool Karim; Carolyn Williamson; Lynn Morris
Journal:  J Virol       Date:  2013-02-13       Impact factor: 5.103

Review 6.  Immunological and virological characteristics of human immunodeficiency virus type 1 superinfection: implications in vaccine design.

Authors:  Yang Gao; Wen Tian; Xiaoxu Han; Feng Gao
Journal:  Front Med       Date:  2017-11-23       Impact factor: 4.592

7.  Reduced frequency of HIV superinfection in a high-risk cohort in Zambia.

Authors:  Evonne Woodson; Debby Basu; Hope Olszewski; Jill Gilmour; Ilene Brill; William Kilembe; Susan Allen; Eric Hunter
Journal:  Virology       Date:  2019-06-15       Impact factor: 3.616

Review 8.  Virological features associated with the development of broadly neutralizing antibodies to HIV-1.

Authors:  Penny L Moore; Carolyn Williamson; Lynn Morris
Journal:  Trends Microbiol       Date:  2015-01-05       Impact factor: 17.079

Review 9.  Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection.

Authors:  Cynthia A Derdeyn; Penny L Moore; Lynn Morris
Journal:  Curr Opin HIV AIDS       Date:  2014-05       Impact factor: 4.283

Review 10.  Structural insights on the role of antibodies in HIV-1 vaccine and therapy.

Authors:  Anthony P West; Louise Scharf; Johannes F Scheid; Florian Klein; Pamela J Bjorkman; Michel C Nussenzweig
Journal:  Cell       Date:  2014-02-13       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.